Prevalence and Effects of Deep Vein Thrombosis on Hospital Outcomes Among COVID-19 Patients
Circulation Conference: American Heart Association's
; 146(Supplement 1), 2022.
Article
in English
| EMBASE | ID: covidwho-2194395
ABSTRACT
Introduction:
Current estimates show that, globally, there are 531 million cases and 6.3 million deaths due to COVID-19. Studies have shown that COVID-19 could lead to deep vein thrombosis (DVT) resulting in increased morbidity and mortality. In this study we sought to estimate the prevalence of DVT among COVID-19 hospitalizations as well as its effects on hospital outcomes using a large administrative database.Hypothesis:
The adverse in-hospital outcomes of COVID-19 will be significantly higher among DVT hospitalizations. Method(s) We conducted a retrospective analysis of the 2020 California State Inpatient Database. All hospitalizations with age 18 and above and primary diagnosis of COVID-19 were included for the study. They were classified into those with and without DVT. The main outcomes of the study were in-hospital mortality, prolonged length of stay, vasopressor use, mechanical ventilation, and ICU admission. Length of stay >=75th percentile was grouped as prolonged length of stay. Multivariate logistic regressions with covariate adjustments were conducted to compare COVID-19 related outcomes between those with and without DVT. Result(s) We included a total of 94,114 primary COVID-19 hospitalizations for the analysis. Among them 1575 (1.7%) had DVT. The prevalence of mortality (27.5% versus 11.1%, P<0.001), prolonged length of stay (62.2% versus 27.8%, P<0.001), vasopressor use (7.9% versus 2.1%, P<0.001), mechanical ventilation (36.2% versus 9.7%, P<0.001), and ICU admission (35.7% versus 9.3%, P<0.001) were significantly higher among those with DVT. After adjusting for covariates, regression analysis showed that those with DVT had significantly greater odds for mortality (aOR, 2.34, 95% CI 2.07-2.65), prolonged length of stay (aOR, 3.51, 95% CI 3.16-3.91), vasopressor use (aOR, 4.23, 95% CI 3.78-4.74), mechanical ventilation (aOR, 2.90, 95% CI 2.38-3.53), and ICU admission (aOR, 4.32, 95% CI 3.85-4.84). Conclusion(s) In our cohort, only few COVID-19 hospitalizations had a diagnosis of DVT. However, among those with DVT, the risk for adverse outcomes were significantly higher. Since DVT among COVID-19 is uncommon but associated with adverse hospital outcomes, healthcare providers should promptly monitor for DVT and manage it.
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Experimental Studies
/
Observational study
Language:
English
Journal:
Circulation Conference: American Heart Association's
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS